Last updated: February 15, 2026
Overview
NDC 59212-0002 corresponds to Taltz (ixekizumab), a monoclonal antibody developed by Eli Lilly for treating psoriatic arthritis, plaque psoriasis, and other inflammatory conditions. Since its FDA approval in 2016, Taltz has established a significant market presence within biologic therapies.
Market Size and Demand
The biologics market for autoimmune diseases is tracking an annual growth rate of 10%-12%. The typical indications for Taltz target a combined patient pool of approximately 6 million globally, with the United States accounting for a substantial share.
- U.S. market: Estimated 2 million potential patients for psoriasis and psoriatic arthritis.
- Global market: Approx. 4 million patients with similar diagnoses.
- Market penetration: Taltz holds around 15% share within its primary indications, behind Humira (adalimumab) and Stelara (ustekinumab).
Competitive Landscape
Major competitors include:
- Humira (adalimumab)
- Stelara (ustekinumab)
- Cosentyx (secukinumab)
- Skyrizi (risankizumab)
Each competitor's annual revenue exceeds $5 billion globally, with Humira leading at over $20 billion. Novo Nordisk's Cosentyx has been gaining market share, pushing prices downward.
Pricing Dynamics
Initial List Price: Approximately $6,000 per dose or roughly $48,000 annually, based on bi-weekly administration.
- Average wholesale price (AWP): Ranges from $6,200 to $6,500 per dose across different regions.
- Patient access and insurance coverage: Significantly influence the actual transaction price, often lowering costs for payers.
Real-World Pricing Trends
Reimbursement adjustments and biosimilar entry influence net prices. The introduction of biosimilars began in 2021, though patent protections and exclusivity periods extend until at least 2025 for Taltz.
Price Projections and Trends
- Short-term (next 1-2 years): No significant price reductions expected due to patent protections and biosimilar market entry delays. Prices may stabilize or slightly decline (~5%) due to payer negotiations.
- Medium-term (3-5 years): Potential price erosion of 15%-25% anticipated following biosimilar launches and increased competition.
- Long-term (beyond 5 years): Possible reductions of up to 40% if biosimilars gain substantial market share, decreasing list prices to approximately $3,600-$4,000 per dose.
Regulatory and Pricing Policy Impact
- Price controls or reimbursement policies in Europe and the U.S. could influence prices.
- Adoption of value-based pricing models may cap list prices and improve payer negotiations.
- Manufacturer sustainment strategies, including label expansions and line extensions, may mitigate price declines.
Patent and Market Exclusivity Timeline
- Patent protection lasts until 2029-2030, with some formulations protected until then.
- Biosimilar approvals are underway, but market entry may be delayed until 2024-2026 due to patent litigations and regulatory processes.
Investment and R&D Implications
Potential pipeline developments include:
- Novel formulations (subcutaneous, long-acting injectables)
- Expanded indications (e.g., Crohn's disease, ankylosing spondylitis)
- Combination therapies
These developments could exert upward pressure on prices via improved efficacy or broadened patient access.
Summary
| Attribute |
Value / Trend |
| Current list price |
~$6,000 per dose |
| Market share |
~15% in key indications |
| Competition |
Humira, Stelara, Cosentyx, Skyrizi |
| Patent protection |
Until 2029-2030 |
| Biosimilar entry |
Expected around 2024-2026 |
| Price decline forecast (next 5 years) |
15%-25% |
| Long-term price range |
$3,600 - $4,000 per dose |
Key Takeaways
- Taltz currently commands high pricing with limited immediate downward pressure.
- Market share growth depends on competition, biosimilar entry, and payer negotiations.
- Biosimilar entry is expected to impact prices within 3-5 years but may be delayed by patent litigations.
- Broadened indications and formulation innovations could sustain or increase prices.
- Regulatory policies in various regions will influence the pace of price erosion.
FAQs
1. How does biosimilar competition affect Taltz's pricing?
Biosimilar competitors planned for 2024-2026 could reduce Taltz’s list price by 15%-25%, contingent on uptake, patent disputes, and regulatory approvals.
2. What are the key factors influencing future price trends?
Patent protections, market penetration of biosimilars, reimbursement policies, and clinical development pipelines primarily drive price changes (upward or downward).
3. How do payer negotiations impact the actual cost to patients?
Rebates, discounts, and formulary placements typically lower the net price for payers, meaning the list price often exceeds what payers effectively pay.
4. Are there any regulatory risks that could further influence prices?
Yes. Policy shifts toward price regulation in major markets could impose caps, affecting profit margins and list prices.
5. When might significant price reductions occur?
Major reductions are likely post-biosimilar market entry (2024-2026), with incremental decreases anticipated over the subsequent 3-5 years.
Sources
[1] IQVIA. "Biologic Drug Market Analysis," 2022.
[2] FDA. "FDA Approval Database," 2016.
[3] Evaluate Pharma. "Biologics Market Forecasts," 2023.
[4] GoodRx. "Biologic Drug Pricing," August 2023.
[5] U.S. Patent and Trademark Office. "Patent Status for Ixekizumab," 2022.
